跳到正文
原文
MedPage Today·· 16 天前精选AI 评分75

个体化癌症疫苗前景可期,但仍需更多研究

Cancer Vaccines Show Promise. But We Have More Work to Do.

AI 导读

个体化癌症疫苗在晚期黑色素瘤中显示出减少复发和远处转移的潜力,但其在其他癌症中的效果尚不明确。研究还需确定哪些患者受益、疫苗与免疫治疗的最佳序贯方案,以及其在不同癌症中的应用前景。

推荐理由

分析了个体化癌症疫苗在肿瘤治疗中的潜在作用及其研究进展,为临床应用提供了参考。

正文

— A look at how individualized cancer vaccines may fit into a complex treatment landscape

by Gilberto de Lima Lopes Junior, MD, MBA

November 4, 2026 • 4 min read

The controversy surrounding the premature disclosure of Moderna and Merck's mRNA melanoma vaccine results risks overshadowing a more consequential clinical discussion: how individualized cancer vaccines might fit into an increasingly effective and increasingly complex treatment landscape.

The results are very encouraging. Reducing recurrence and distant metastases by adding a treatment with a new mechanism to an effective checkpoint inhibitor represent meaningful progress. Our work now is to determine which patients benefit, how vaccination should be sequenced with other treatments, and whether its promise extends beyond melanoma.

In INTerpath-001, which randomized 1,137 patients with completely resected stage IIB–IV melanoma, results presented at ESMO showed 2-year recurrence-free survival of 82.2% with the mRNA-based cancer vaccine intismeran autogene plus pembrolizumab (Keytruda) versus 70% with placebo plus pembrolizumab. The absolute difference was 12.2 percentage points; the hazard ratio was 0.58 (95% CI, 0.45-0.75). At a median follow-up of 24.6 months, an overall survival benefit had not been demonstrated.

Preventing recurrence has clinical value. It can spare patients further treatment and morbidity. But not all patients benefited from the intervention, and these findings do not establish efficacy across other cancers.

The biological rationale behind intismeran autogene is compelling. Personalized mRNA vaccines encode tumor-specific neoantigens that antigen-presenting cells process and present to prime and expand tumor-reactive T cells. PD-1 blockade complements this response by reducing inhibitory signaling that limits T-cell activity. Vaccination may therefore broaden tumor-directed immunity while checkpoint inhibition supports its function. INTerpath-001 demonstrates the benefit of adding vaccination to pembrolizumab; without a vaccine-only arm, it cannot formally establish synergy.

This approach brings together tumor sequencing, computational antigen selection, mRNA delivery, and immunotherapy. Yet a predicted neoantigen is not necessarily an effective immune target. Translational studies must clarify which responses control the cancer clones responsible for recurrence.

The vaccine discussion also needs to account for progress in neoadjuvant immunotherapy. In SWOG S1801, beginning pembrolizumab before surgery improved event-free survival compared with administering it entirely afterward. In NADINA, neoadjuvant nivolumab-ipilimumab followed by surgery and response-directed postoperative therapy improved event-free survival compared with surgery followed by nivolumab (Opdivo).

These advances make sequencing a central research question. Could vaccination improve outcomes after neoadjuvant immunotherapy? Might patients without a major pathological response have the greatest need? Conversely, could patients with a major response avoid additional treatment?

INTerpath-001 does not answer these questions. Nor can cross-trial comparisons, as populations, endpoints, and treatment strategies differ. The neoadjuvant question is particularly relevant to patients with clinically apparent, resectable stage III disease; it should not obscure the vaccine findings in other patients represented in the trial.

We need studies that integrate advances in treatment rather than simply accumulate postoperative therapies. Residual disease after checkpoint inhibition also does not necessarily imply vaccine sensitivity. That hypothesis requires testing.

Beyond melanoma, our optimism must remain tempered by the evidence. Tumors differ in antigen availability, antigen presentation, immune infiltration, and mechanisms of immune suppression. Still, early findings justify investigation and enthusiasm. A phase I pancreatic cancer study demonstrated persistent vaccine-induced T-cell responses in some patients receiving an individualized mRNA vaccine alongside atezolizumab and chemotherapy. Immune responders had longer recurrence-free survival than nonresponders.

This establishes biological activity, not that vaccination improves outcomes in pancreatic cancer. The study was small, lacked a randomized control group, and compared patients according to their immune response. A randomized trial is evaluating the combination more rigorously.

Patient selection deserves similar discipline. Pathological response and circulating tumor DNA are attractive candidates for refining postoperative decisions. But identifying patients at higher risk of recurrence is different from identifying those more likely to benefit from vaccination. Biomarker-guided treatment strategies require prospective evaluation.

Delivery is another clinical endpoint in practice. In INTerpath-001, vaccine production was successful for more than 99% of patients assigned to intismeran, an encouraging feasibility result. Median time to the first vaccine dose was 64 days. That interval is not simply a manufacturing-time estimate, but it makes treatment coordination -- and the feasibility of preoperative vaccination -- important research questions.

Safety also requires attention. Grade 3-5 treatment-related adverse events occurred in 14.2% of patients receiving intismeran plus pembrolizumab versus 13.4% of those receiving pembrolizumab alone. However, all-cause adverse events led to discontinuation of any study drug in 16.6% versus 9.5%, respectively. Similar rates of severe treatment-related toxicity do not establish an identical treatment burden.

Regulators must evaluate manufacturing consistency alongside efficacy and safety. Clinicians need durable outcomes, patient-reported quality of life, and practical delivery data. Health systems must determine whether treatment is feasible and affordable beyond specialized centers.

As an oncologist working in clinical development and global cancer care, I would place access within the development agenda from the beginning. Adequate tissue, sequencing capacity, production infrastructure, and coverage and reimbursement will determine who benefits.

Personalized cancer vaccines could become an important component of perioperative treatment. Their greatest contribution may come through careful integration with checkpoint inhibition, response assessment, and better patient selection. Our responsibility is to translate an encouraging result into longer and better lives, while avoiding unnecessary treatment, toxicity, and financial burden.

来源:MedPage Today · medpagetoday.com